Summit Therapeutics plc

Stock Exchange: XLON; XNAS Ticker: SUMM; SMMT HQ: Abingdon, UK Employees: 40 Signatory to Davos Decl: No Signatory to Industry Roadmap: No
Performance by research area
How Summit Therapeutics plc was evaluated
1 2.1 2.2 2.3 3 4
R&D A
1 2 3
M&P B
1 2 3 4 5 6 7
AA&S C
Applicable indicator Not applicable

Performance

Summit is a biopharmaceutical company, selected for having a pipeline that targets priority pathogens. It was evaluated in the area of Research & Development only. It invested USD 5 million in antibiotic drug development in 2016. The company performs well compared to other biopharmaceutical companies in scope. It has one project in its antimicrobial R&D pipeline targeting priority pathogens. Summit engages in public-private partnerships to develop its antibiotic candidates. The company reports that it has an access commitment in place for its antibiotic candidate in late-stage development, but reports no information on stewardship provisions.

Operations

Summit is a biopharmaceutical company focussing on the development of novel medicines for indications for which current therapies are lacking or inadequate. The company was founded in 2003 as a spin-off from the University of Oxford and is currently conducting two clinical programmes: one on the genetic disease Duchenne muscular dystrophy and the other on C. difficile infections (CDI). Its only antimicrobial drug candidate is ridinilazole, currently in Phase II development. The compound is designed to selectively target C. difficilebacteria without disrupting the gut flora, thereby reducing CDI recurrence rates—a common clinical issue in this disease. The company plans to start Phase III trials for ridinilazole in the first half of 2018. Summit has no products on the market. In September 2017, the company was awarded a contract from BARDA of up to USD 62 million for the development of ridinilazole for the treatment of CDI. In December 2017, Summit acquired UK-based Discuva Ltd, a biotechnology company with a proprietary genetics-based platform facilitating the discovery and development of differentiated antibiotics. Summit was listed on the AIM market of the London stock exchange in 2004, after raising GBP 15 million from investors. In 2015, it was listed on the NASDAQ stock exchange, where it raised USD 34 million.

Antimicrobial Portfolio

Summit does not have any products on the market.

Opportunities

Plan ahead for access and stewardship during R&D.

Summit has committed to ensure access and stewardship provisions are in place for its antibiotic candidate (ridinilazole), through its agreement with the Wellcome Trust. It can ensure that these plans are applied and implemented accordingly.

A. Research & Development

Indicators scored on
  • 1
  • 2.1
  • 2.2
  • 2.3
  • 3
  • 4
Antimicrobial pipeline
1 projects, 1 target priority pathogens

A.2.1-2.2 One novel antibiotic in the clinical pipeline. 

Biopharmaceutical companies in scope were selected based on their pipelines that target priority bacteria. Summit invested USD 5 million in antibiotic drug development in 2016. The company has one project in its antimicrobial R&D pipeline targeting a priority pathogen. Summit’s antimicrobial pipeline consists of the antibiotic ridinilazole, currently in clinical Phase II development for the treatment of CDI. The drug candidate is a bis-benzimidazole, a new class of antibiotics for which the mode of action is yet unknown.

A.3 One R&D project being developed with public partners. 

Summit is developing one R&D project in its priority pathogen pipeline through public-private partnership (including non-profit organisations). The company has received GBP 6.3 million from the Wellcome Trust for the preclinical and clinical development of ridinilazole. Under the agreement, Summit is solely responsible for the preclinical and clinical development of the CDI programme. The Wellcome Trust is eligible to receive a tiered portion of the net revenue made by Summit or its affiliates (of up to a low- to mid-single digit percentage) following signing of a revenue share agreement in 2017. The Wellcome Trust is also eligible to receive a milestone of a specified amount if cumulative net revenues exceed a specified amount. In addition, in September 2017, the company was granted up to USD 62 million by BARDA for advancing the clinical and regulatory development of ridinilazole, including through Phase III clinical trials.

A.4 Access commitment in place, but no information regarding stewardship. 

Summit reports that it has an access commitment in place for its antibiotic candidate in latestage development, but reports no information on stewardship provisions. The access commitment for its investigational antibiotic (ridinilazole) has been made through an agreement with the Wellcome Trust. If the company or its licensees do not develop, commercialise or exercise their IP rights in underserved markets within a specified timeframe, the Wellcome Trust is permitted to take over exploitation of the IP in those markets. The IP rights were granted to Summit for a number of major territories including the United States, Europe and Japan. No specific strategy has been made for lower- and middle- income countries. For this indicator, countries in scope are 106 low- and middle-income countries where access to medicine is likely limited.

Pipeline targeting priority pathogens

Enlarge

B. Manufacturing & Production

As a biopharmaceutical company with no products on the market, Summit was not eligible for this Research Area.

C. Appropriate Access & Stewardship

As a biopharmaceutical company with no products on the market, Summit was not eligible for this Research Area.



Got a question?

Learn more

View our detailed overview of each company’s performance